Posts Tagged: drug discovery

Induced Pluripotent Stem Cells 10 Years Later For Cardiac Applications

Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications

Yoshinori Yoshida, Shinya Yamanaka

Factors which possibly cause clonal differences of induced pluripotent stem cells (iPSCs). [Powerpoint File]

Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications

Induced Pluripotent Stem Cells 10 Years Later: For Cardiac Applications

Yoshinori Yoshida, Shinya Yamanaka

Patient stratification based on drug responsiveness using induced pluripotent stem cells–derived cardiac myocytes. [Powerpoint File]

Finding the Rhythm of Sudden Cardiac Death: New Opportunities Using Induced Pluripotent Stem Cell–Derived Cardiomyocytes

Finding the Rhythm of Sudden Cardiac Death: New Opportunities Using Induced Pluripotent Stem Cell–Derived Cardiomyocytes

Karim Sallam*, Yingxin Li*, Philip T. Sager, Steven R. Houser, Joseph C. Wu

Potential role for iPSC-CMs in evaluation of patients with known or at risk for arrhythmic disorders. Clinical genetic testing attempts to identify a rare variant in genes commonly associated with arrhythmic disorders. When a known variant is identified, this may aid the clinical diagnosis and genetic screening can be offered to family members to identify those at risk for developing the disorder. If a variant of uncertain significance (VUS) is identified, genome-edited lines with VUS can be developed, and cellular EP testing can be done on the resultant iPSC-CMs to detect electrophysiological abnormalities and compare them to proband iPSC-CMs. This may help re-characterize the VUS as possibly disease causing and place it in a similar category as a known variant. In cases where EP testing of the VUS is negative or inconclusive or no variants are identified on genetic testing, one can ignore the genetic component and use iPSC-CMs as the cellular functional testing platform (EP study in a dish). iPSC-CMs from the proband would be created and undergo comprehensive EP testing; abnormalities thus identified may be used to aid in the diagnosis and management of the patient. Furthermore, family members could be offered the opportunity to have iPSC-CMs generated and screened for their arrhythmic predisposition. Much like genetic testing, iPSC-CM testing may not identify all arrhythmic abnormalities, and those patients are left to rely on clinical testing and screening (Illustration credit: Ben Smith). [Powerpoint File]